MLCommons' AI training tests show that the more chips you have, the more critical the network that's between them.

When it comes to fully photonic networking, the proposition for data center operators is an alluring one. “There are no electrical packet switches at all,” says James Regan of the novel light-based ...

Dr. Juho Jalkanen, CEO of Faron Pharmaceuticals, said:"We are thrilled to see bexmarilimab's data receive acceptance for oral presentation at EHA, following similar recognition at MDS and ASCO.

At this year's ASCO meeting, IBI363 reported encouraging Phase 1/2 clinical data in the first three indications explored—non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and melanoma ...

Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other ...

has announced the presentation of updated clinical data for the ongoing Phase 1 trial for EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

IBI363 shows remarkable efficacy in immune-resistant wild-type nsclc and clinical data suggests better trends in ORR, DCR, PFS and OS at higher doses. We expect longer-term follow-up to bring more ...

Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3 rd-generation EGFR inhibitors and outperforms other investigational 4 th-generation ...

Intel may sell its network and edge units to refocus on its PC and data center chip core amid rising AI competition. CEO Lip-Bu Tan plans to build on Intel's 68% PC chip share as rivals like ...

IBI363 shows remarkable efficacy in immune-resistant wild-type nsclc and clinical data suggests better trends in ORR, DCR, PFS and OS at higher doses. We expect longer-term follow-up to bring more ...

Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML Oral presentation at EHA will include updated data at the 40 mg ...

“The House of Dior recently discovered that an unauthorized external party accessed some of the data we hold for our Dior Fashion and Accessories customers,” stated the spokesperson.